title: Quality indicators in ovarian cancer surgery: report from the French Society of Gynecologic Oncology (Societe Francaise d'Oncologie Gynecologique, SFOG).
abstract: BACKGROUND
  Based on registries, the European experience has been that <50% of patients are treated according to protocols and/or benefit from the minimum required surgery for ovarian cancer. The French Cancer Plan 2009-2013 considers the definition of qualitative indicators in ovarian cancer surgery in France. This endeavour was undertaken by the French Society of Gynaecologic Oncology (SFOG) in partnership with the French National College of Obstetricians and Gynecologists and all concerned learned societies in a multidisciplinary mindset.
  
  
  METHODS
  The quality indicators for the initial management of patients with ovarian cancer were based on the standards of practice determined from scientific evidence or expert consensus.
  
  
  RESULTS
  The indicators were divided into structural indicators, including material (equipment), human (number and qualification of staff), and organizational resources, process indicators, and outcome indicators.
  
  
  CONCLUSIONS
  The enforcement of a quality assurance programme in any country would undoubtedly promote improvement in the quality of care for ovarian cancer patients and would result in a dramatic positive impact on their survival. Such a policy is not only beneficial to the patient, but is also profitable for the healthcare system.
authors.affiliation: Department of Surgery, Institut Claudius Regaud, Toulouse, France.
authors.forename: D
authors.initials: D
authors.lastname: Querleu
authors.forename: I
authors.initials: I
authors.lastname: Ray-Coquard
authors.forename: J M
authors.initials: JM
authors.lastname: Classe
authors.forename: J S
authors.initials: JS
authors.lastname: Aucouturier
authors.forename: F
authors.initials: F
authors.lastname: Bonnet
authors.forename: P
authors.initials: P
authors.lastname: Bonnier
authors.forename: E
authors.initials: E
authors.lastname: Darai
authors.forename: M
authors.initials: M
authors.lastname: Devouassoux
authors.forename: L
authors.initials: L
authors.lastname: Gladieff
authors.forename: O
authors.initials: O
authors.lastname: Glehen
authors.forename: C
authors.initials: C
authors.lastname: Haie-Meder
authors.forename: F
authors.initials: F
authors.lastname: Joly
authors.forename: F
authors.initials: F
authors.lastname: Lécuru
authors.forename: J P
authors.initials: JP
authors.lastname: Lefranc
authors.forename: C
authors.initials: C
authors.lastname: Lhommé
authors.forename: P
authors.initials: P
authors.lastname: Morice
authors.forename: A
authors.initials: A
authors.lastname: Salengro
authors.forename: E
authors.initials: E
authors.lastname: Stoeckle
authors.forename: S
authors.initials: S
authors.lastname: Taieb
authors.forename: Z X
authors.initials: ZX
authors.lastname: Zeng
authors.forename: E
authors.initials: E
authors.lastname: Leblanc
mesh_terms: D005260:Female; D005602:France; D006801:Humans; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000601:surgery*; D010053:Ovary / Q000473:pathology / Q000601:surgery; D011785:Quality Assurance, Health Care; D019984:Quality Indicators, Health Care
keywords: gynaecologic oncology; ovarian cancer; quality assurance; surgical oncology